Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Benzbromarone is a potent uricosuric agent primarily utilized in the management of chronic gout and hyperuricemia. Chemically identified by its CAS number 1089-53-2, this compound possesses the molecular formula C₁₉H₁₆Br₂O₄. Structurally, it belongs to the bromobenzofuran class of drugs, characterized by two bromine atoms attached to a benzene ring fused with a furan moiety. Its mechanism of action involves the selective inhibition of organic anion transporter 4 (OAT4) and URAT1 in the proximal renal tubules. By blocking these transporters, Benzbromarone effectively reduces the reabsorption of uric acid from the urine back into the bloodstream, thereby significantly increasing urinary excretion of urate and lowering serum uric acid levels.
Originally developed as a non-narcotic analgesic with anti-inflammatory properties, its clinical focus shifted decisively toward its powerful uricosuric effects. It is particularly valuable for patients who do not respond adequately to xanthine oxidase inhibitors like allopurinol or febuxostat, or for those with underexcretory gout where increased elimination is required. Unlike some other agents, Benzbromarone does not inhibit uric acid production but rather enhances its removal, making it highly efficient in dissolving existing tophi and preventing new crystal formation over time. However, due to rare but serious reports of hepatotoxicity, including acute liver failure, its use has been restricted or banned in several countries, including the United States and parts of Europe. Consequently, it remains available in specific markets such as Japan, China, and certain Latin American nations, often requiring strict monitoring of liver function tests before and during therapy. Despite safety concerns, it continues to serve as a critical therapeutic option for refractory gout cases when used with caution and appropriate patient selection. The drug is typically administered orally in tablet form, with dosing adjusted based on individual renal function and baseline uric acid concentrations to maximize efficacy while minimizing potential adverse events.